Annual report pursuant to Section 13 and 15(d)

Balance Sheet Account Details - Contingent Liabilities (Details)

v3.20.4
Balance Sheet Account Details - Contingent Liabilities (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Oct. 01, 2020
Apr. 01, 2020
Contingent Liability [Roll Forward]        
Commercial rights at beginning of period $ 8,942 $ 12,542    
Additional Contingent Liabilities 41,800      
Payments (2,325) (3,050)    
Fair Value Adjustment 963 (30)    
Repurchases (247) (520)    
Commercial rights at end of period 49,133 8,942    
Cydex        
Contingent Liability [Roll Forward]        
Commercial rights at beginning of period 348 514    
Additional Contingent Liabilities 0      
Payments 0 (50)    
Fair Value Adjustment 160 (116)    
Repurchases 0 0    
Commercial rights at end of period 508 348    
Metabasis        
Contingent Liability [Roll Forward]        
Commercial rights at beginning of period 5,935 5,551    
Additional Contingent Liabilities 0      
Payments 0 0    
Fair Value Adjustment (1,867) 904    
Repurchases (247) (520)    
Commercial rights at end of period 3,821 5,935    
Crystal        
Contingent Liability [Roll Forward]        
Commercial rights at beginning of period 2,659 6,477    
Additional Contingent Liabilities 0      
Payments (1,800) (3,000)    
Fair Value Adjustment (59) (818)    
Repurchases 0 0    
Commercial rights at end of period 800 2,659    
Icagen        
Business Acquisition [Line Items]        
Contingent consideration liability       $ 25,000
Contingent Liability [Roll Forward]        
Commercial rights at beginning of period 0 0    
Additional Contingent Liabilities 4,800      
Payments (525) 0    
Fair Value Adjustment 2,129 0    
Repurchases 0 0    
Commercial rights at end of period 6,404 0    
Pfenex        
Business Acquisition [Line Items]        
Contingent consideration liability per share (USD per share)     $ 2.00  
Contingent consideration liability     $ 77,800  
Contingent Liability [Roll Forward]        
Commercial rights at beginning of period 0 0    
Additional Contingent Liabilities 37,000      
Payments 0 0    
Fair Value Adjustment 600 0    
Repurchases 0 0    
Commercial rights at end of period $ 37,600 $ 0